PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 ...

Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $9.00 price target ...

Reports FY24 revenue $25.3M, consensus $25.15M. “We are pleased with the significant PEMGARDA revenue growth of 48% in the fourth quarter, ...

Invivyd reported Q4 2024 revenue of $13.8 million, highlighting significant growth and ongoing development of COVID-19 treatments PEMGARDA and VYD2311. Invivyd, Inc. reported a net product revenue ...

March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial ...

(RTTNews) - Invivyd, Inc. (IVVD) announced Loss for full year that decreased from the same period last year but missed the Street estimates. The company's bottom line totaled -$169.93 million ...

Invivyd has a 52 week low of $0.35 and a 52 week high of $4.74. The firm has a market cap of $86.12 million, a price-to-earnings ratio of -0.37 and a beta of 0.09.

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.67 per share a year ago. These figures are ...